TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $23.84 million. The enterprise value is $20.21 million.
| Market Cap | 23.84M |
| Enterprise Value | 20.21M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 0.23% in one year.
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 22.72% |
| Float | 9.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.29 |
| Forward PS | n/a |
| PB Ratio | 0.88 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | 7.64 |
| P/OCF Ratio | 7.64 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 6.48 |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.22 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.78 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1.08% and return on invested capital (ROIC) is -7.31%.
| Return on Equity (ROE) | -1.08% |
| Return on Assets (ROA) | -2.88% |
| Return on Invested Capital (ROIC) | -7.31% |
| Return on Capital Employed (ROCE) | -5.38% |
| Weighted Average Cost of Capital (WACC) | 6.34% |
| Revenue Per Employee | $3.27M |
| Profits Per Employee | -$217,000 |
| Employee Count | 1 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TherapeuticsMD has paid $32,000 in taxes.
| Income Tax | 32,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.34% in the last 52 weeks. The beta is 0.65, so TherapeuticsMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +94.34% |
| 50-Day Moving Average | 2.11 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 47.05 |
| Average Volume (20 Days) | 17,481 |
Short Selling Information
The latest short interest is 26,437, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 26,437 |
| Short Previous Month | 26,387 |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.28% |
| Short Ratio (days to cover) | 0.75 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $3.27 million and -$217,000 in losses. Loss per share was -$0.02.
| Revenue | 3.27M |
| Gross Profit | 3.27M |
| Operating Income | -1.75M |
| Pretax Income | -263,000 |
| Net Income | -217,000 |
| EBITDA | -1.37M |
| EBIT | -1.75M |
| Loss Per Share | -$0.02 |
Balance Sheet
The company has $9.19 million in cash and $5.56 million in debt, with a net cash position of $3.63 million or $0.31 per share.
| Cash & Cash Equivalents | 9.19M |
| Total Debt | 5.56M |
| Net Cash | 3.63M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 27.13M |
| Book Value Per Share | 2.34 |
| Working Capital | 11.12M |
Cash Flow
| Operating Cash Flow | 3.12M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 382,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 3.12M |
| FCF Per Share | $0.27 |
Margins
Gross margin is 100.00%, with operating and profit margins of -53.55% and -6.64%.
| Gross Margin | 100.00% |
| Operating Margin | -53.55% |
| Pretax Margin | -8.04% |
| Profit Margin | -6.64% |
| EBITDA Margin | -41.87% |
| EBIT Margin | -53.55% |
| FCF Margin | 95.41% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | -0.23% |
| Earnings Yield | -0.91% |
| FCF Yield | 13.09% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 47.51% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
TherapeuticsMD has an Altman Z-Score of -34.09 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.09 |
| Piotroski F-Score | 4 |